|Bid||12.50 x 800|
|Ask||13.33 x 3100|
|Day's Range||12.75 - 13.73|
|52 Week Range||8.65 - 19.24|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
BOSTON and LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today summarized recent accomplishments and 2019 strategic priorities in conjunction with its attendance at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. Mark Rothera, president and chief executive officer, will present a business overview outlining the company’s progress as a global leader in gene therapy on Wednesday, January 9, 2019 at 3:00 p.m. PT that will be webcast at ir.orchard-tx.com. “2018 was a momentous year for Orchard, marked by the success of our acquisition and integration of GSK’s rare disease ex-vivo gene therapy portfolio, initial scaling of our manufacturing capabilities and completion of our initial public offering,” said Mr. Rothera.
BOSTON and LONDON, Jan. 02, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.
Person to watch Jennifer Cook The 25-year Genentech veteran — most recently in charge of clinical operations — after a year on the job is leading early cancer diagnostics company Grail toward a potential $500 million IPO. Grail is also launching a 50,000-person study to see if its technology can detect multiple cancer types earlier, particularly lung cancer. Technology to watch AI / ML From Daphne Koller’s Insitro to Alice Zhang’s Verge Genomics Inc., artificial intelligence and machine learning are moving beyond hype to real-time lab use.
Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ), a rare disease gene therapy company, recently went public, offering 14.29 million shares at $14 each. The shares were listed on the Nasdaq Oct. 31 and ended ...
Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.
BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Alicia Secor to its board of directors. Ms. Secor brings more than 25 years of life sciences leadership and commercial product expertise with a particular focus in rare disease and other areas of unmet need, most recently serving as president and chief executive officer at Juniper Pharmaceuticals, Inc.
BOSTON and LONDON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that Scientific Advisory Board Member, Donald B. Kohn, MD, presented clinical proof-of-concept data from an ongoing academic clinical trial evaluating OTL-102 for the treatment of X-Linked Chronic Granulomatous Disease (X-CGD) during the Presidential Symposium at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition on December 4, 2018. X-CGD is a life-threatening inherited immunodeficiency disorder which is caused by a genetic mutation that results in the inability of neutrophils to effectively kill bacterial and fungal pathogens.
Commercial team preparing for potential gene therapy launches BOSTON and LONDON, Nov. 08, 2018 -- Orchard Therapeutics, a leading commercial-stage biotech company.
BOSTON and LONDON, Nov. 05, 2018 -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and.
Two stocks that were making their debut on Wednesday were lower in afternoon trade, failing to benefit from the overall market's sharp gains. Shares of Orchard Therapeutics Plc , a biotech that specializes in ex vivo gene therapies, was last down 1.8%. The company sold 14.3 million shares priced at $14 to raise $200.2 million. Shares are trading on Nasdaq under the ticker symbol "ORTX". Axonics Modulation Technologies Inc.'s shares were down 1%. That company, which specializes in sacral neuromodulation treatments for overactive bladder and urinary retention among other disorders, sold 8 million shares at $15 to raise $120 million. The Dow Jones Industrial Average was last up 426 points, or 1.7%, while the S&P 500 was up 52 points, or 1.9%.
Orchard Therapeutics PLC priced its initial public offering at $14 per American Depositary Share. The biotech that specializes in ex vivo gene therapies sold 14.3 million shares to raise $200.2 million. Shares will start trading later Wednesday on Nasdaq under the ticker symbol "ORTX". JPMorgan, Goldman Sachs and Cowen were lead underwriters on the deal with Wedbush acting as co-manager.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates are expected, not confirmed, at time of publication. BankFlorida (BFL) will issue 6.2 million shares between ...